ClinicalTrials.Veeva

Menu

Neurostimulation for Sleep Disordered Breathing (SDB) (ECLIPSE 2)

L

Lunair Medical

Status

Enrolling

Conditions

Sleep Disordered Breathing (SDB)
Sleep Apnea

Treatments

Device: Neuro stimulator implant

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

This is a study to determine if the Lunair Alpha System is safe and effective for treating moderate to severe sleep disordered breathing.

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject does not tolerate, not compliant to, or have access to alternative Sleep Disordered Breathing treatments
  • Subject has moderate to severe sleep disordered breathing as diagnosed by PSG

Exclusion criteria

  • Subject is taking opioids, narcotics, sleep or psychotic medications or supplements that may alter consciousness, the pattern of respiration, sleep architecture, or with known effect on sleep-wake function or alertness.
  • Any reason for which, in the judgement of the investigator, the subject is considered to be a poor study candidate
  • Subject has previous upper respiratory tract (URT) surgery or procedure (e.g., uvula, soft palate or tonsils) within 60 days prior to Screening PSG.
  • Subject has a need for chronic supplemental oxygen therapy for any reason
  • Subject has other sleep disorders or sleep hygiene behaviors that confound functional assessments of sleepiness
  • Subject has severe chronic kidney disease
  • Subject exhibits ongoing misuse of alcohol, tobacco, caffeine, or recreational drugs that would impact either the results of or the participation in a sleep study
  • Subject conducts work or regular activities requiring vigilance
  • Subject is unwilling or unable to refrain from consumption of alcoholic beverages for 24 hours prior to the start of each PSG study
  • Subject is unwilling or unable to refrain from sleep disordered breathing treatments or devices
  • Subject has an active systemic infection at the time of implant
  • Subject has clinical evidence of immunodeficiency
  • Any condition likely to require future MRI or diathermy
  • Subject is pregnant
  • Subject has severe nasal obstruction that could restrict airflow
  • Subject has any trauma to the upper airway
  • Subject has previous surgical resection, prior or current radiation therapy for cancer or congenital malformations in the larynx, tongue, or throat

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

45 participants in 1 patient group

Alpha Lunair System implanted subjects
Experimental group
Treatment:
Device: Neuro stimulator implant

Trial contacts and locations

1

Loading...

Central trial contact

Kris VP, Clinical Operations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems